Screener
Hemab Therapeutics Holdings, Inc. COAG Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Hemab Therapeutics Holdings, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The source filing: Hemab Therapeutics Holdings, Inc.’s 10-Q, filed August 11, 2026. Open the filing →
- Filed
- Aug 11, 2026, 4:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-344533
FAQ
- What is Hemab Therapeutics Holdings, Inc.'s cash & equivalents?
- Hemab Therapeutics Holdings, Inc. (COAG) reported cash & equivalents of $237.37M in Q2 2026.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about Hemab Therapeutics Holdings, Inc.'s cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude